|
122 Companies |
|
196 Products |
|
196 Products |
|
116 Mechanisms of Action |
|
3 Trials |
|
2338 News |
|
| «12...56789101112131415...4647» |
- Enrollment change, Trial suspension: PET Imaging in Chronic Traumatic Encephalopathy (clinicaltrials.gov) - May 10, 2016
P=N/A, N=6, Suspended, Sponsor: National Institute of Mental Health (NIMH)
N=40 --> 6 | Recruiting --> Suspended
- Enrollment change, Trial suspension: Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease (clinicaltrials.gov) - May 10, 2016
P=N/A, N=195, Suspended, Sponsor: National Institute of Mental Health (NIMH)
N=40 --> 6 | Recruiting --> Suspended N=550 --> 195 | Recruiting --> Suspended
- ||| Trial completion: Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants (clinicaltrials.gov) - May 5, 2016
P1, N=52, Completed, Sponsor: Hoffmann-La Roche
N=550 --> 195 | Recruiting --> Suspended Active, not recruiting --> Completed
- Trial termination, Trial primary completion date: Neurological Complications - Pulmonary Transplant (clinicaltrials.gov) - May 5, 2016
P=N/A, N=0, Terminated, Sponsor: Hopital Foch
Active, not recruiting --> Completed Recruiting --> Terminated | Trial primary completion date: Sep 2015 --> Mar 2013; Recruitment difficulties
- Enrollment closed: ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement (clinicaltrials.gov) - May 5, 2016
P=N/A, N=160, Active, not recruiting, Sponsor: Duke University
Recruiting --> Terminated | Trial primary completion date: Sep 2015 --> Mar 2013; Recruitment difficulties Recruiting --> Active, not recruiting
- rivastigmine transdermal / Generic mfg.
Trial completion: X-MEN: Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients (clinicaltrials.gov) - May 5, 2016
P=N/A, N=300, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment change, Trial termination: Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025 (clinicaltrials.gov) - May 3, 2016
P3, N=348, Terminated, Sponsor: FORUM Pharmaceuticals Inc
Recruiting --> Completed N=1000 --> 348 | Suspended --> Terminated; Study has been suspended due to clinical hold.
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment change, Trial termination: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - May 3, 2016
P3, N=403, Terminated, Sponsor: FORUM Pharmaceuticals Inc
N=1000 --> 348 | Suspended --> Terminated; Study has been suspended due to clinical hold. N=790 --> 403 | Suspended --> Terminated; Study has been suspended due to clinical hold.
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment change, Trial termination: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease (clinicaltrials.gov) - May 3, 2016
P3, N=474, Terminated, Sponsor: FORUM Pharmaceuticals Inc
N=790 --> 403 | Suspended --> Terminated; Study has been suspended due to clinical hold. N=790 --> 474 | Suspended --> Terminated; Study has been suspended due to clinical hold.
- Trial completion, Trial primary completion date, Surgery: POPE: Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery (clinicaltrials.gov) - May 3, 2016
P4, N=20, Completed, Sponsor: Karolinska University Hospital
N=790 --> 474 | Suspended --> Terminated; Study has been suspended due to clinical hold. Enrolling by invitation --> Completed | Trial primary completion date: Jun 2015 --> Feb 2016
- Trial primary completion date: Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment (clinicaltrials.gov) - Apr 22, 2016
P3, N=200, Active, not recruiting, Sponsor: Thomas Jefferson University
Enrolling by invitation --> Completed | Trial primary completion date: Jun 2015 --> Feb 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Victoza (liraglutide) / Novo Nordisk
Trial primary completion date: Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=80, Recruiting, Sponsor: Stanford University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2016 --> Feb 2017
- || Trial completion: Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) (clinicaltrials.gov) - Apr 21, 2016
P3, N=50, Completed, Sponsor: Seoul National University Bundang Hospital
Trial primary completion date: Feb 2016 --> Feb 2017 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: VTIME: A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=302, Completed, Sponsor: Tel-Aviv Sourasky Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Apr 2014 --> Apr 2015
- | MK-7622 / Merck (MSD)
Enrollment change, Trial termination: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Apr 19, 2016
P2a, N=240, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=830 --> 240 | Active, not recruiting --> Terminated; Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.
- || Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change, Trial primary completion date: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=450, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
The trial was terminated at Stage 1; did not proceed to Stage 2. N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018
- |||| Trial completion, Trial primary completion date: Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (clinicaltrials.gov) - Apr 18, 2016
P2, N=151, Completed, Sponsor: Purimed Co., Ltd.
N=360 --> 450 | Trial primary completion date: Aug 2017 --> Feb 2018 Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Sep 2014
- ||| Trial completion, Enrollment change, Trial primary completion date: Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease (clinicaltrials.gov) - Apr 18, 2016
P=N/A, N=55, Completed, Sponsor: Accera, Inc.
Recruiting --> Completed | Trial primary completion date: Feb 2013 --> Sep 2014 Enrolling by invitation --> Completed | N=200 --> 55 | Trial primary completion date: May 2012 --> Oct 2012
- donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Enrollment change, Trial termination, HEOR: COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=200, Terminated, Sponsor: Indiana University
Enrolling by invitation --> Completed | N=200 --> 55 | Trial primary completion date: May 2012 --> Oct 2012 N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early.
- donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Adverse events: A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=57, Completed, Sponsor: Sunnybrook Health Sciences Centre
N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early. Recruiting --> Completed | N=180 --> 57 | Trial primary completion date: Dec 2018 --> Jan 2016
- Trial completion, Surgery: Perfusion Pressure Cerebral Infarction Trial (PPCI) (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=197, Completed, Sponsor: Rigshospitalet, Denmark
Recruiting --> Completed | N=180 --> 57 | Trial primary completion date: Dec 2018 --> Jan 2016 Recruiting --> Completed
- ||||||| LMTX (hydromethylthionine) / TauRx
Trial completion: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Apr 11, 2016
P3, N=891, Completed, Sponsor: TauRx Therapeutics Ltd
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| LMTX (hydromethylthionine) / TauRx
Trial completion, Trial initiation date: Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (clinicaltrials.gov) - Apr 11, 2016
P3, N=220, Completed, Sponsor: TauRx Therapeutics Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Aug 2013 --> May 2013
- Trial primary completion date: Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects (clinicaltrials.gov) - Apr 9, 2016
P1, N=80, Recruiting, Sponsor: Molecular NeuroImaging
Active, not recruiting --> Completed | Initiation date: Aug 2013 --> May 2013 Trial primary completion date: Feb 2016 --> Dec 2016
- Trial completion: Self-management and Cognitive Function in Adults With Heart Failure (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=372, Completed, Sponsor: Kent State University
Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Completed
- || Enrollment closed, Trial primary completion date: Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants (clinicaltrials.gov) - Apr 7, 2016
P1, N=52, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Completed --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016
- Enrollment closed, Enrollment change: ACES: The Aerobic & Cognitive Exercise Study (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=111, Active, not recruiting, Sponsor: Union College, New York
Completed --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Apr 2016 Recruiting --> Active, not recruiting | N=90 --> 111
- Enrollment closed: ATP in Alzheimer Disease (clinicaltrials.gov) - Apr 1, 2016
P2, N=20, Active, not recruiting, Sponsor: Sara Varea
Recruiting --> Active, not recruiting | N=90 --> 111 Recruiting --> Active, not recruiting
- ||| Trial completion: Effect of NeuroAD on the Cognitive Function of Alzheimer Patients (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=131, Completed, Sponsor: Neuronix Ltd
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease (clinicaltrials.gov) - Mar 29, 2016
P=N/A, N=28, Active, not recruiting, Sponsor: Ohio State University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016
- Trial primary completion date: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=18, Recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- || MK-7622 / Merck (MSD)
Trial primary completion date: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) (clinicaltrials.gov) - Mar 25, 2016
P2a, N=830, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Apr 2018 --> Apr 2016
- Enrollment change: Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL) (clinicaltrials.gov) - Mar 25, 2016
P=N/A, N=78, Completed, Sponsor: VA Office of Research and Development
Trial primary completion date: Apr 2018 --> Apr 2016 N=160 --> 78
- tetrabenazine / Generic mfg.
Trial primary completion date: Effect of Tetrabenazine on Stroop Interference in HD (clinicaltrials.gov) - Mar 24, 2016
P4, N=10, Recruiting, Sponsor: New York Medical College
N=160 --> 78 Trial primary completion date: Jan 2016 --> Jan 2018
- Trial completion: CONCEPT: Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients (clinicaltrials.gov) - Mar 22, 2016
P=N/A, N=125, Completed, Sponsor: General Hospital Groeninge
Trial primary completion date: Jan 2016 --> Jan 2018 Recruiting --> Completed
- haloperidol / Generic mfg.
Phase classification, Enrollment change, Trial termination, Trial primary completion date: ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium (clinicaltrials.gov) - Mar 21, 2016
P3, N=40, Terminated, Sponsor: University of Pittsburgh
Recruiting --> Completed Phase classification: P2 --> P3 | N=304 --> 40 | Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Oct 2011; Insufficient recruitment to meet aims.
- | donepezil / Generic mfg.
Enrollment closed: Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318) (clinicaltrials.gov) - Mar 21, 2016
P2, N=36, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P2 --> P3 | N=304 --> 40 | Recruiting --> Terminated | Trial primary completion date: Dec 2010 --> Oct 2011; Insufficient recruitment to meet aims. Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=41, Completed, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2011
- haloperidol / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Surgery: HALPCARD: Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium (clinicaltrials.gov) - Mar 19, 2016
P3, N=25, Active, not recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2011 Recruiting --> Active, not recruiting | N=40 --> 25 | Trial primary completion date: Apr 2016 --> Sep 2015
- Enrollment closed, Enrollment change: Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs) (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=510, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | N=40 --> 25 | Trial primary completion date: Apr 2016 --> Sep 2015 Recruiting --> Active, not recruiting | N=416 --> 510
- Trial primary completion date, Combination therapy: Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI) (clinicaltrials.gov) - Mar 17, 2016
P4, N=330, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting | N=416 --> 510 Trial primary completion date: Jul 2015 --> Jul 2016
- Enrollment closed: Tailored Activity Program-Veterans Affairs (clinicaltrials.gov) - Mar 17, 2016
P1, N=160, Active, not recruiting, Sponsor: VA Office of Research and Development
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Active, not recruiting
- |||| sembragiline (RO4602522) / Roche, Evotec
Trial completion: MAyflOwer RoAD: A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy (clinicaltrials.gov) - Mar 14, 2016
P2, N=531, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: PEARL-HD: [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (clinicaltrials.gov) - Mar 14, 2016
P0, N=90, Recruiting, Sponsor: CHDI Foundation, Inc.
Active, not recruiting --> Completed N=60 --> 90
- Trial completion, Enrollment change, Trial primary completion date: Treating Cancer-Related Fatigue Through Systematic Light Exposure (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=54, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
N=60 --> 90 Recruiting --> Completed | N=75 --> 54 | Trial primary completion date: Jan 2016 --> Jul 2014
- Trial primary completion date: Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=41, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Completed | N=75 --> 54 | Trial primary completion date: Jan 2016 --> Jul 2014 Trial primary completion date: Jul 2015 --> Jul 2016
- Trial completion, Trial primary completion date: Alzheimer's Disease Multiple Intervention Trial (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=180, Completed, Sponsor: Indiana University
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Dec 2015
- dexmedetomidine / Generic mfg.
Surgery: Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery (clinicaltrials.gov) - Mar 8, 2016
P4, N=63, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Dec 2015 N=132 --> 63
- | Biomarker, Trial completion, Enrollment change, Trial primary completion date: A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=20, Completed, Sponsor: Sanguine Biosciences
N=132 --> 63 Recruiting --> Completed | N=600 --> 20 | Trial primary completion date: Oct 2015 --> Mar 2015
- Enrollment change, Trial primary completion date: 2-StaLi: Cognitive Outcome After Two-stage Liver-Operation (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=40, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed | N=600 --> 20 | Trial primary completion date: Oct 2015 --> Mar 2015 N=30 --> 40 | Trial primary completion date: Feb 2016 --> Jan 2017